bacteriophage cocktail (University of California, San Diego)

This is an investigational bacteriophage cocktail being developed by the University of California, San Diego (UC San Diego). It is being evaluated for the treatment of antibiotic-resistant bacterial infections in patients with cystic fibrosis (CF). The therapy consists of a cocktail of multiple bacteriophages, which are naturally occurring viruses that target and destroy specific bacterial species. A specific formulation mentioned contains four phages targeting *Pseudomonas aeruginosa*, a common cause of chronic lung infections in CF patients. The treatment is being studied in the TAPT (Taking Advantage of Phage Technologies) Phase 1 clinical trial, where it is administered intravenously in combination with standard antibiotics. The research is led by UC San Diego's Center for Innovative Phage Applications and Therapeutics (IPATH). [9, 14, 15]

Other names

bacteriophage cocktail-University of California, San Diego-cystic fibrosis-bacterial infection